|Bid||50.90 x 1100|
|Ask||51.10 x 2200|
|Day's range||49.99 - 50.85|
|52-week range||42.48 - 63.69|
|Beta (3Y monthly)||0.59|
|PE ratio (TTM)||13.32|
|Earnings date||31 Oct 2019|
|Forward dividend & yield||1.64 (3.28%)|
|1y target est||58.13|
Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil
Bristol-Myers Squibb Company will host a webcast on Saturday, September 28, 2019 at 7:30 p.m. CEST to discuss data presented at the European Society of Medical Oncology, in Barcelona, Spain.
Giovanni Caforio has been the CEO of Bristol-Myers Squibb Company (NYSE:BMY) since 2015. This analysis aims first to...
Overall survival data from CheckMate -227 Part 1 evaluating Opdivo plus low-dose Yervoy in advanced non-small cell lung cancer featured in ESMO Presidentia
The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to reduce the risk of cardiovascular death or worsening of heart failure in adult patients with HFrEF and HFpEF.
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its NMOSD drug in a phase III study.
Zacks Market Edge Highlights: UnitedHealth, Centene, MasTec, Bank of America and Bristol-Myers Squibb
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its MS drug in a phase III study.
Year to date, the performance on Wall Street is projecting a glorious picture with no end to the bull run in sight, at least this year.
Bristol-Myers Squibb Company will announce results for the third quarter of 2019 on Thursday, October 31, 2019. During a conference call at 8:30 a.m. ET on October 31, company executives will review financial information and will address inquiries from investors and analysts.
The Board of Directors of Bristol-Myers Squibb Company today declared a quarterly dividend of forty one cents per share on the $.10 par value Common Stock of the corporation.